State Street Corp Increases Holdings in Pulse Biosciences, Inc. (NASDAQ:PLSE)

State Street Corp increased its position in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) by 17.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 461,333 shares of the company's stock after buying an additional 69,696 shares during the period. State Street Corp owned about 0.75% of Pulse Biosciences worth $8,092,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in Pulse Biosciences by 6.7% in the second quarter. Rhumbline Advisers now owns 25,729 shares of the company's stock valued at $288,000 after buying an additional 1,608 shares in the last quarter. Quest Partners LLC acquired a new stake in shares of Pulse Biosciences during the 2nd quarter worth about $91,000. Bank of New York Mellon Corp lifted its stake in Pulse Biosciences by 23.4% during the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company's stock worth $570,000 after purchasing an additional 9,639 shares during the last quarter. Creative Planning boosted its holdings in Pulse Biosciences by 113.9% in the third quarter. Creative Planning now owns 21,910 shares of the company's stock valued at $384,000 after purchasing an additional 11,667 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Pulse Biosciences in the third quarter valued at approximately $588,000. Institutional investors and hedge funds own 76.95% of the company's stock.

Pulse Biosciences Price Performance

PLSE traded down $0.71 on Friday, reaching $18.02. The company had a trading volume of 102,315 shares, compared to its average volume of 199,230. The stock has a 50-day moving average price of $18.02 and a 200-day moving average price of $16.77. Pulse Biosciences, Inc. has a 1 year low of $6.59 and a 1 year high of $22.69.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter in the prior year, the firm posted ($0.19) earnings per share.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Pulse Biosciences to a "sell" rating in a research report on Tuesday.

Insider Activity

In other Pulse Biosciences news, CEO Burke Thomas Barrett sold 50,000 shares of Pulse Biosciences stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total value of $871,000.00. Following the sale, the chief executive officer now owns 63,172 shares of the company's stock, valued at approximately $1,100,456.24. The trade was a 44.18 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert W. Duggan acquired 56,054 shares of the company's stock in a transaction that occurred on Wednesday, December 11th. The shares were acquired at an average cost of $17.35 per share, for a total transaction of $972,536.90. Following the acquisition, the director now directly owns 42,228,057 shares of the company's stock, valued at $732,656,788.95. This trade represents a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 71.50% of the company's stock.

Pulse Biosciences Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.